These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1520 related items for PubMed ID: 21208597

  • 1. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, Roth T.
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [Abstract] [Full Text] [Related]

  • 2. Validation of the sleep impact scale in patients with major depressive disorder and insomnia.
    Lasch K, Joish VN, Zhu Y, Rosa K, Qiu C, Crawford B.
    Curr Med Res Opin; 2009 Jul; 25(7):1699-710. PubMed ID: 19505198
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
    Walsh JK, Soubrane C, Roth T.
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):44-57. PubMed ID: 18165461
    [Abstract] [Full Text] [Related]

  • 4. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder.
    Fava M, Asnis GM, Shrivastava R, Lydiard B, Bastani B, Sheehan D, Roth T.
    J Clin Psychopharmacol; 2009 Jun; 29(3):222-30. PubMed ID: 19440075
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T, Soubrane C, Titeux L, Walsh JK, Zoladult Study Group.
    Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
    [Abstract] [Full Text] [Related]

  • 6. Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms.
    Barkin RL.
    Am J Ther; 2007 Aug; 14(3):299-305. PubMed ID: 17515707
    [Abstract] [Full Text] [Related]

  • 7. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
    Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T.
    Biol Psychiatry; 2006 Jun 01; 59(11):1052-60. PubMed ID: 16581036
    [Abstract] [Full Text] [Related]

  • 8. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study.
    Dorsey CM, Lee KA, Scharf MB.
    Clin Ther; 2004 Oct 01; 26(10):1578-86. PubMed ID: 15598474
    [Abstract] [Full Text] [Related]

  • 9. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun 01; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 10. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age.
    Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD.
    Pediatrics; 2009 May 01; 123(5):e770-6. PubMed ID: 19403468
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L, Andersen HF, Reines EH.
    Curr Med Res Opin; 2005 Oct 01; 21(10):1659-68. PubMed ID: 16238906
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
    Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T, ZOLONG Study Group.
    Sleep; 2008 Jan 01; 31(1):79-90. PubMed ID: 18220081
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov 01; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 14. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
    Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L.
    Obstet Gynecol; 2006 Dec 01; 108(6):1402-10. PubMed ID: 17138773
    [Abstract] [Full Text] [Related]

  • 15. A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression.
    Krystal AD, Harsh JR, Yang R, Rippon GA, Lankford DA.
    J Clin Psychiatry; 2010 Jan 01; 71(1):32-40. PubMed ID: 20051221
    [Abstract] [Full Text] [Related]

  • 16. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Jan 01; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial.
    Lydiard RB, Lankford DA, Seiden DJ, Landin R, Farber R, Walsh JK.
    J Clin Sleep Med; 2006 Jul 15; 2(3):309-15. PubMed ID: 17561543
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 15; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 19. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun 15; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 20. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH, Cutler AJ, Richards C, Lasser R, Geibel BB, Gao J, Sambunaris A, Patkar AA.
    J Clin Psychiatry; 2013 Aug 15; 74(8):802-9. PubMed ID: 24021497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.